• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The Influence of the Microbiome on NAFLD and NASH.微生物群对非酒精性脂肪性肝病和非酒精性脂肪性肝炎的影响。
Clin Liver Dis (Hoboken). 2021 Feb 1;17(1):15-18. doi: 10.1002/cld.1010. eCollection 2021 Jan.
2
Non-alcoholic fatty liver and the gut microbiota.非酒精性脂肪肝与肠道微生物群
Mol Metab. 2016 Jun 14;5(9):782-94. doi: 10.1016/j.molmet.2016.06.003. eCollection 2016 Sep.
3
Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.微生物群与非酒精性脂肪性肝病：有氧运动能力和生活方式改变的潜在影响
Physiol Genomics. 2017 Aug 1;49(8):385-399. doi: 10.1152/physiolgenomics.00012.2017. Epub 2017 Jun 9.
4
Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.与儿童非酒精性脂肪性肝病患者的脂肪性肝炎和中重度纤维化相关的微生物组特征。
Gastroenterology. 2019 Oct;157(4):1109-1122. doi: 10.1053/j.gastro.2019.06.028. Epub 2019 Jun 27.
5
Gut microbiome and nonalcoholic fatty liver diseases.肠道微生物群与非酒精性脂肪性肝病
Pediatr Res. 2015 Jan;77(1-2):245-51. doi: 10.1038/pr.2014.157. Epub 2014 Oct 13.
6
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.综述文章：细菌可以成为药物吗？益生菌和益生元作为非酒精性脂肪性肝病治疗手段的潜力。
Aliment Pharmacol Ther. 2019 Sep;50(6):628-639. doi: 10.1111/apt.15416. Epub 2019 Aug 2.
7
The role of the microbiome in NAFLD and NASH.微生物组在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
EMBO Mol Med. 2019 Feb;11(2). doi: 10.15252/emmm.201809302.
8
Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.综述文章：肠道微生物组在非酒精性脂肪性肝病进展中的新作用及其潜在的治疗意义。
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314. Epub 2019 May 31.
9
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.分子机制：非酒精性脂肪性肝病、脂肪性肝炎和肝细胞癌之间的联系。
Int J Mol Sci. 2020 Feb 23;21(4):1525. doi: 10.3390/ijms21041525.
10
The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD.肠道微生物群和益生菌对非酒精性脂肪性肝病患者的治疗意义
Diseases. 2019 Feb 25;7(1):27. doi: 10.3390/diseases7010027.

引用本文的文献

1
Deep sequencing-derived Metagenome Assembled Genomes from the gut microbiome of liver transplant patients.来自肝移植患者肠道微生物群的深度测序衍生宏基因组组装基因组
Sci Data. 2025 Jan 9;12(1):39. doi: 10.1038/s41597-024-04153-8.
2
The influence of perilipin 5 deficiency on gut microbiome profiles in murine metabolic dysfunction-associated fatty liver disease (MAFLD) and MAFLD-hepatocellular carcinoma.载脂蛋白 5 缺乏对代谢相关脂肪性肝病（MAFLD）和 MAFLD-肝细胞癌小鼠肠道微生物组谱的影响。
Front Cell Infect Microbiol. 2024 Oct 14;14:1443654. doi: 10.3389/fcimb.2024.1443654. eCollection 2024.
3
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments.代谢功能障碍相关脂肪性肝病在肠道各区域表现出性别特异性的微生物异质性。
Clin Mol Hepatol. 2025 Jan;31(1):179-195. doi: 10.3350/cmh.2024.0359. Epub 2024 Oct 11.
4
Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment.非酒精性脂肪性肝炎：对风险因素、症状及治疗的全面更新综述
Heliyon. 2024 Mar 25;10(7):e28468. doi: 10.1016/j.heliyon.2024.e28468. eCollection 2024 Apr 15.
5
Microbial Dysbiosis Linked to Metabolic Dysfunction-Associated Fatty Liver Disease in Asians: Promotes Lipopolysaccharide Biosynthesis and Network Instability in the Prevotella Enterotype.亚洲人代谢功能相关脂肪性肝病与微生物失调有关：促进普雷沃氏菌肠型内脂多糖的生物合成和网络不稳定。
Int J Mol Sci. 2024 Feb 11;25(4):2183. doi: 10.3390/ijms25042183.
6
NASH/NAFLD-Related Hepatocellular Carcinoma: An Added Burden.非酒精性脂肪性肝炎/非酒精性脂肪性肝病相关肝细胞癌：一项额外负担。
Life (Basel). 2023 Dec 23;14(1):25. doi: 10.3390/life14010025.
7
Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets.肠道微生物组和肝脏在非酒精性脂肪性肝病（NAFLD）中的免疫：机制、细菌和新的治疗靶点。
Arch Microbiol. 2024 Jan 13;206(2):62. doi: 10.1007/s00203-023-03752-0.
8
Exploring public interest in gut microbiome dysbiosis, NAFLD, and probiotics using Google Trends.使用谷歌趋势探索公众对肠道微生物失调、非酒精性脂肪性肝病和益生菌的兴趣。
Sci Rep. 2024 Jan 8;14(1):799. doi: 10.1038/s41598-023-50190-5.
9
Alanyl-Glutamine Dipeptide Attenuates Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice by Improving Gut Microbiota Dysbiosis.丙氨酰-谷氨酰胺二肽通过改善肠道微生物失调减轻高脂饮食诱导的小鼠非酒精性脂肪肝疾病。
Nutrients. 2023 Sep 14;15(18):3988. doi: 10.3390/nu15183988.
10
- A Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease.一种用于非酒精性脂肪性肝病的潜在下一代益生菌。
Curr Pharm Biotechnol. 2024;25(4):426-433. doi: 10.2174/1389201025666230915103052.

本文引用的文献

1
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.奥贝胆酸治疗非酒精性脂肪性肝炎：多中心、随机、安慰剂对照 3 期临床试验的中期分析。
Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5.
2
Role of gut microbiota in liver disease.肠道微生物群在肝脏疾病中的作用。
Am J Physiol Gastrointest Liver Physiol. 2020 Jan 1;318(1):G84-G98. doi: 10.1152/ajpgi.00118.2019. Epub 2019 Oct 28.
3
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.非酒精性脂肪性肝病相关肝硬化的肠道微生物组特征。
Nat Commun. 2019 Mar 29;10(1):1406. doi: 10.1038/s41467-019-09455-9.
4
FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.法尼醇 X 受体依赖性调控胆汁酸衍生物奥贝胆酸对人类小肠微生物组的作用
Gastroenterology. 2018 Dec;155(6):1741-1752.e5. doi: 10.1053/j.gastro.2018.08.022. Epub 2018 Aug 23.
5
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.基于肠道微生物群的宏基因组特征用于非侵入性检测人类非酒精性脂肪性肝病中的晚期纤维化
Cell Metab. 2017 May 2;25(5):1054-1062.e5. doi: 10.1016/j.cmet.2017.04.001.
6
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.胆汁酸与非酒精性脂肪性肝病：分子见解与治疗前景
Hepatology. 2017 Jan;65(1):350-362. doi: 10.1002/hep.28709. Epub 2016 Aug 4.
7
Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats.奥贝胆酸可减少肝硬化大鼠细菌易位并抑制肠道炎症。
J Hepatol. 2016 May;64(5):1049-1057. doi: 10.1016/j.jhep.2015.12.010. Epub 2015 Dec 23.
8
Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus.肠道微生物群改变可独立于糖尿病预测肝硬化患者的住院情况。
Sci Rep. 2015 Dec 22;5:18559. doi: 10.1038/srep18559.
9
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.非酒精性脂肪性肝病的严重程度与肠道菌群失调及肠道微生物群代谢功能的改变有关。
Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13.
10
MyD88 Adaptor-Dependent Microbial Sensing by Regulatory T Cells Promotes Mucosal Tolerance and Enforces Commensalism.调节性T细胞通过依赖MyD88衔接蛋白的微生物感知促进黏膜耐受并维持共生关系。
Immunity. 2015 Aug 18;43(2):289-303. doi: 10.1016/j.immuni.2015.06.014. Epub 2015 Jul 28.

微生物群对非酒精性脂肪性肝病和非酒精性脂肪性肝炎的影响。

The Influence of the Microbiome on NAFLD and NASH.

作者信息

Albhaisi Somaya A M, Bajaj Jasmohan S

机构信息

Department of Internal Medicine Virginia Commonwealth University Richmond VA.

Division of Gastroenterology, Hepatology, and Nutrition Department of Internal Medicine Virginia Commonwealth University and McGuire VA Medical Center Richmond VA.

出版信息

Clin Liver Dis (Hoboken). 2021 Feb 1;17(1):15-18. doi: 10.1002/cld.1010. eCollection 2021 Jan.

DOI:10.1002/cld.1010
PMID:33552480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7849305/
Abstract

Watch a video presentation of this article Watch an interview with the author.

摘要

观看本文的视频演示。观看对作者的采访。